Answers are grounded in this paper and cite their sources.
Preclinical pharmacokinetic study reveals low oral bioavailability of hecogenin in male ICR mice, highlighting the need for delivery strategies to improve systemic absorption.
Hecogenin, a steroidal sapogenin from agave plants, exhibits anti‐inflammatory, anti‐tumor, gastroprotective, and diuretic activities. A sensitive ultraperformance liquid chromatography–tandem mass spectrometry (UPLC‐MS/MS) method was developed and validated for quantifying hecogenin in mouse whole blood using swertisin as internal standard. Protein precipitation with acetonitrile enabled simple pretreatment of only 20‐μL blood samples. Separation was achieved on a BEH C18 column with gradient elution, and detection was performed via multiple reaction monitoring in positive electrospray ionization mode. The assay was linear over 1–2000 ng/mL ( r = 0.9988), with a lower limit of quantification of 1 ng/mL. Intra‐ and interday precision (RSD) were below 11% and 12%, respectively, and accuracy ranged from 93.2% to 110.4%. Matrix effects were negligible, and extraction recovery was 87.5%–91.2%. The validated method was applied to a pharmacokinetic study in male ICR mice following intravenous (5 mg/kg) and oral (10, 20 mg/kg) administration. Noncompartmental analysis revealed low oral absolute bioavailability (10.8%–12.4%).
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: